Showing results (131-140 of 184) with videos related to

Sort By:
Pageof 19
Journal of Crohn'S & Colitis|June 5, 2021
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational CohortsLauranne A A P Derikx, Heather W Dolby, Nikolas Plevris, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)G T Ho, A Mowat, L Potts, et al.
Alimentary Pharmacology & Therapeutics|January 10, 2009
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-upC W Lees, A I Ali, A I Thompson, et al.
The American Journal of Gastroenterology|August 16, 2022
The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD)Hassan Azhari, James A King, Stephanie Coward, et al.
Inflammatory Bowel Diseases|August 21, 2023
Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United KingdomSamuel Hsiang Lim, Beatriz Gros, Esha Sharma, et al.
Plos Medicine|December 17, 2008
Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathwaysCharlie W Lees, William J Zacharias, Mark Tremelling, et al.
Inflammatory Bowel Diseases|February 8, 2007
Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort studyZhigang Liu, Kaixing Le, Xin Zhou, et al.
Gut|September 9, 2011
NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2Aleixo M Muise, Wei Xu, Cong-Hui Guo, et al.
Alimentary Pharmacology & Therapeutics|February 20, 2016
Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysisN A Kennedy, B Warner, E L Johnston, et al.
Pageof 19